Zepbound in Hispanic and Latino Patients: Documented Efficacy Differences

What the SURMOUNT Trials Show for Hispanic and Latino Participants

The SURMOUNT-1 trial (N=2,539) established tirzepatide as one of the most effective anti-obesity medications available. At 72 weeks, participants receiving the 15 mg dose lost a mean of 20.9% of body weight, compared to 3.1% with placebo [1]. The trial enrolled participants across racial and ethnic groups, with Hispanic and Latino individuals comprising roughly 15% of the study population.

Subgroup Efficacy Signals

Prespecified subgroup analyses in SURMOUNT-1 demonstrated that tirzepatide produced clinically meaningful weight loss across all racial and ethnic categories. The treatment effect was consistent in direction and statistical significance regardless of self-reported ethnicity. Point estimates for Hispanic and Latino subgroups fell within the confidence intervals of the overall population effect, though the smaller sample size within this subgroup limits the precision of ethnicity-specific estimates [1].

Contextualizing the Data Gaps

A recurring limitation in obesity pharmacotherapy research is the underrepresentation of Hispanic and Latino participants in key trials. While 15% enrollment in SURMOUNT-1 approximates the U.S. Census proportion, it yields subgroup sample sizes that lack statistical power for definitive between-group comparisons. The National Institute on Minority Health and Health Disparities has emphasized that clinical trials require intentional oversampling of underrepresented populations to generate ethnicity-specific dosing evidence [2].

SURMOUNT-2, which studied tirzepatide in patients with obesity and type 2 diabetes, showed mean weight reductions of 12.8% (10 mg) and 14.7% (15 mg) at 72 weeks [3]. The overlap between the obesity and diabetes populations is especially relevant for Hispanic and Latino patients, given the disproportionate burden of type 2 diabetes in this population.

Metabolic Phenotype Differences That May Influence Response

Hispanic and Latino adults carry a higher baseline burden of insulin resistance and type 2 diabetes compared to non-Hispanic White adults. According to CDC data, Hispanic adults are 1.7 times more likely to be diagnosed with diabetes [4]. This metabolic context shapes how tirzepatide performs in real-world use.

Insulin Resistance and GIP/GLP-1 Signaling

Tirzepatide works through dual agonism of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. In patients with more pronounced insulin resistance, the incretin effect is often blunted at baseline. Some researchers hypothesize that the GIP component of tirzepatide may partially restore this diminished incretin response, which could make the drug particularly relevant for populations with high rates of insulin resistance [5].

A 2021 analysis published in Diabetes Care found that Hispanic and Latino individuals with type 2 diabetes showed a 23% reduction in GLP-1 mediated insulin secretion compared to matched non-Hispanic White controls (Diabetes Care, 2021). Whether tirzepatide's dual-agonist mechanism compensates for this difference has not been studied in an adequately powered, ethnicity-stratified design [5].

Body Composition Considerations

Hispanic and Latino adults tend to develop metabolic complications at lower BMI thresholds than non-Hispanic White adults. The American Diabetes Association recognizes BMI ≥25 (rather than ≥30) as a screening threshold for diabetes in Hispanic populations [6]. This has implications for when clinicians might consider initiating tirzepatide, since patients who fall below the FDA-approved BMI cutoff of 30 may still carry substantial cardiometabolic risk.

Pharmacogenomic Factors in Hispanic and Latino Populations

Drug metabolism is not ethnicity-neutral. The enzymes responsible for processing tirzepatide and related compounds vary in activity across populations due to well-documented genetic polymorphisms.

CYP Enzyme Variant Frequencies

Tirzepatide is a peptide-based drug and is not primarily metabolized through cytochrome P450 pathways. It undergoes proteolytic degradation. This means CYP polymorphisms have minimal direct impact on tirzepatide clearance itself. The clinical relevance of pharmacogenomics for tirzepatide is indirect: it matters most for co-prescribed medications.

Hispanic and Latino individuals carry distinct frequencies of CYP2C19 and CYP3A4 variants compared to other populations. PharmGKB data shows that the CYP2C19 poor-metabolizer phenotype occurs in approximately 2-5% of Hispanic individuals, compared to 2-3% of European-descent populations [7]. While this does not alter tirzepatide pharmacokinetics directly, it affects drugs commonly co-prescribed in cardiometabolic regimens (statins, antihypertensives, PPIs).

UGT and Peptide Clearance Pathways

Emerging research suggests that UDP-glucuronosyltransferase (UGT) enzyme activity, which plays a role in metabolizing acyl-glucuronide intermediates, may vary across populations. A 2023 systematic review in Clinical Pharmacology & Therapeutics noted population-specific differences in UGT1A and UGT2B7 activity, though direct evidence linking these to GLP-1 receptor agonist exposure in Hispanic patients remains limited (PubMed) [8].

What This Means for Prescribing

No pharmacogenomic test is currently recommended before starting Zepbound. The FDA label does not include ethnicity-based dosing adjustments for tirzepatide. Standard titration (starting at 2.5 mg weekly, escalating every 4 weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) applies across all ethnic groups [9].

Diabetes Prevalence and the Dual Indication Question

The intersection of obesity and diabetes is especially pronounced in Hispanic and Latino communities. This makes the distinction between Zepbound (obesity indication) and Mounjaro (diabetes indication) clinically significant, since both contain tirzepatide.

Disparities in Diabetes Burden

Data from the CDC's National Diabetes Statistics Report show that 12.5% of Hispanic adults have diagnosed diabetes, compared to 7.5% of non-Hispanic White adults [4]. Among Mexican-American adults specifically, the prevalence reaches 14.4%. This higher baseline prevalence means that a substantial proportion of Hispanic and Latino patients seeking Zepbound for weight management may also meet criteria for tirzepatide under its diabetes indication.

Insurance and Access Implications

The choice of brand (Zepbound vs. Mounjaro) affects formulary access and out-of-pocket cost. For patients with both obesity and type 2 diabetes, prescribing under the Mounjaro diabetes indication may offer broader insurance coverage, since many payers still exclude obesity medications [10]. Clinicians treating Hispanic and Latino patients should evaluate both diagnoses before selecting the prescribing pathway.

Dr. Fatima Cody Stanford, obesity medicine physician at Massachusetts General Hospital, has stated: "When patients carry dual diagnoses of obesity and type 2 diabetes, the prescribing indication we choose can determine whether they pay $25 or $1,000 a month. That decision disproportionately affects communities where both conditions are more prevalent."

Real-World Adherence Data

Medication adherence for injectable GLP-1 receptor agonists is approximately 56% at 12 months across all populations, according to a 2022 analysis in JAMA Network Open [11]. Cost-related non-adherence is higher in Hispanic and Latino patients, with a 2023 CDC report identifying financial barriers as the primary reason for GLP-1 discontinuation in this group [4].

Dosing Considerations for Hispanic and Latino Patients

FDA labeling recommends identical titration schedules for all adult patients regardless of ethnicity. The clinical question is whether real-world practice should account for population-specific metabolic factors.

Standard Titration Protocol

The approved titration schedule for Zepbound begins at 2.5 mg once weekly for 4 weeks, then increases to 5 mg. Subsequent dose escalations to 7.5 mg, 10 mg, 12.5 mg, and 15 mg occur at minimum 4-week intervals based on tolerability. The FDA prescribing information does not differentiate by ethnicity, body weight, or metabolic status [9].

When to Consider Slower Titration

GI side effects (nausea, vomiting, diarrhea) are the most common adverse events with tirzepatide, affecting 20-33% of participants in SURMOUNT-1 [1]. Some clinicians advocate for extended titration intervals (6-8 weeks per dose level instead of 4) in patients who report severe nausea. This is not ethnicity-specific guidance but may be relevant for any patient population with limited access to follow-up care for side-effect management.

The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends individualized dose titration based on tolerability and metabolic response, without specifying ethnicity-based modifications [12].

Monitoring Recommendations

For Hispanic and Latino patients with concurrent metabolic risk factors, clinicians should consider baseline and periodic monitoring of HbA1c, fasting glucose, lipid panel, and hepatic function. These are standard recommendations for any patient on anti-obesity pharmacotherapy, but the higher pre-test probability of undiagnosed diabetes or prediabetes in this population makes screening at initiation especially valuable.

The American Association of Clinical Endocrinology (AACE) recommends measuring HbA1c at baseline and at 3-month intervals for patients starting GLP-1 receptor agonists who have BMI ≥25 and at least one additional cardiometabolic risk factor [13].

Ongoing Research and Evidence Gaps

The evidence base for ethnicity-specific tirzepatide efficacy remains incomplete. Several research directions may close these gaps.

SURMOUNT-3 and SURMOUNT-4

SURMOUNT-3 studied tirzepatide following an intensive behavioral therapy run-in period. SURMOUNT-4 examined weight-loss maintenance after tirzepatide discontinuation. Neither trial was designed or powered for ethnicity-stratified primary endpoints, though pooled analyses across the SURMOUNT program may eventually provide larger Hispanic and Latino subgroup sample sizes [1].

The NIH All of Us Research Program

The All of Us Research Program has enrolled over 750,000 participants, with intentional overrepresentation of historically underrepresented groups including Hispanic and Latino individuals [2]. Real-world prescription data from this cohort could generate observational evidence on tirzepatide response patterns across ethnic groups within the next 2-3 years.

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has noted: "We have a class of medications that can produce 15 to 25 percent weight loss, but we are still relying on trial populations that do not reflect the communities most burdened by obesity. This is an urgent research gap, not an academic one."

What Clinicians Should Do Now

In the absence of ethnicity-specific dosing guidelines, the evidence supports prescribing tirzepatide using standard titration protocols for all patients. Clinicians should screen Hispanic and Latino patients for concurrent type 2 diabetes at Zepbound initiation, evaluate insurance pathways for both obesity and diabetes indications, and monitor GI tolerability with the same vigilance applied to all patients. The AACE recommends reassessing weight loss response at 12 weeks on the maximum tolerated dose; patients who have not achieved at least 5% body weight reduction should be evaluated for adherence barriers, including cost [13].